Axillary brachial plexus block with ropivacaine 7.5 mg/ml

Ræder, J.; Drøsdahl, S.; Klaastad, Øivind; Kvalsvik, O.; Isaksen, B.; Strømskag, Kjell Erik; Mowinckel, Petter; Bergheim, R.; Selander, Dag

doi:10.1034/j.1399-6576.1999.430802.x

Cited by 78 publications

(30 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With regard to the blocking effects of bupivacaine and ropivacaine on peripheral nerves, most studies have reported that the onset time and duration of blockade are comparable at similar doses [3,12,13,17]. However, Åker-man et al [1] administered comparable doses of bupivacaine or ropivacaine epidurally to guinea pigs and reported Fig.…”

Section: Discussionmentioning

confidence: 99%

Relative Nerve Blocking Properties of Bupivacaine and Ropivacaine in Dogs Undergoing Brachial Plexus Block Using a Nerve Stimulator

Sakonju

Maeda

Maekawa

et al. 2009

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

ABSTRACT. In the present study, the efficacy of a nerve stimulator in performing brachial plexus block (BPB) in dogs was investigated. The nerve blocking effects of bupivacaine and ropivacaine for BPB were also compared. Twelve beagles were allocated to groups based on the following treatments: conventional BPB with 0.5% bupivacaine (0.5% BupiM group) or BPB with 0.5% bupivacaine, 0.5% ropivacaine or 0.75% ropivacaine and a nerve stimulator (the 0.5% BupiS, 0.5% RopiS and 0.75% RopiS groups, respectively). After BPB, nerve blocking effects were assessed based on sensory blockade in several cutaneous areas and knuckling. The ratio of full block (blockade in all cutaneous areas) for 0.5% BupiM was 25%, and that for 0.5% BupiS was significantly higher, 75% (p<0.05). For the 0.5% BupiS, 0.5% RopiS and 0.75% RopiS groups, the average duration of full block was 387, 184 and 275 min, respectively, and the average duration of knuckling was 703, 460 and 421 min, respectively. The duration of full block and knuckling for the two ropivacaine groups was shorter compared with that of the 0.5% BupiS group. In conclusion, when using bupivacaine and ropivacaine for BPB in dogs, it is worth noting that there are differences in onset time and duration and that effective perioperative analgesia can be achieved depending on the intended use.KEY WORDS: brachial plexus block, bupivacaine, canine, nerve stimulator, ropivacaine.

show abstract

Section: Discussionmentioning

confidence: 99%

Relative Nerve Blocking Properties of Bupivacaine and Ropivacaine in Dogs Undergoing Brachial Plexus Block Using a Nerve Stimulator

Sakonju

Maeda

Maekawa

et al. 2009

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

show abstract

“…Pharmacokinet. 2002, NO.1 (10). The lower and different systemic toxicity of ropivacaine, compared to bupivacaine, makes it possible to use ropivacaine at higher doses, without increasing the risk for the patient.…”

Section: Discussionmentioning

confidence: 99%

Pharmacokinetics and efficacy of 40 ml ropivacaine 7.5 mg/ml (300 mg), for axillary brachial plexus block — an open pilot study

Wank¹,

Büttner

Maier

et al. 2002

Eur. J. Drug Metab. Pharmacokinet.

Self Cite

View full text Add to dashboard Cite

In this study, the pharmacokinetics, tolerability and efficacy of 40 ml of ropivacaine 7.5 mg/ml (300 mg) for axillary brachial plexus block were investigated. With institutional review board approval, 10 patients presenting for surgery of the upper limb were enrolled in this open study. The axillary plexus was identified with a nerve stimulator and the study drug was injected into the neurovascular sheath. Fifteen venous blood samples were obtained from each patient for pharmacokinetic measurements over a 24-h period. All blocks were sufficient for surgery after 45 min without any need for supplemental analgesia or general anesthesia. The mean (SD) peak plasma concentration was 2.3 (0.8) mg/l at median tmax 54 min (range 16-92 min). The mean (SD) maximum free plasma concentration was calculated to be 0.12 (0.06) mg/l (range 0.07-0.29 mg/l). The t 1/2 was about 6 h. There were no clinical signs or symptoms of central nervous system and/or cardiac toxicity in any patient. Ropivacaine 7.5 mg/ml, used in a dose of 300 mg, was effective and well tolerated for axillary brachial plexus block.

show abstract

“…[19] also observed that there was no difference in duration of blockade (9-11 hours) when ropivacaine 7.5% and bupivacaine 0.5% used for axillary brachial blockade.…”

Section: Discussionmentioning

confidence: 85%

“…[19] studied 0.5% ropivacaine and 0.5% bupivacaine for interscalene brachial plexus block and observed duration of analgesia 11±5 hrs after 0.5% ropivacaine and 10.9±3.9 hrs after 0.5% bupivacaine.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Compar Ison Study of Bupivacaine, Levobupivacaine and Ropivacaine in Axillary Brachial Plexus Block: A Clinical Study

Mehrotra¹,

Baghel²,

Gupta³

2015

jemds

View full text Add to dashboard Cite

AIMAim of our study was to assess effect of 0.5% bupivacaine, 0.5% levobupivacaine and 0.5% ropivacaine in axillary brachial plexus block. OBJECTIVETo compare the onset time and duration of sensory and motor blockade of 0.5% bupivacaine, 0.5% levobupivacaine and 0.5% ropivacaine in axillary brachial plexus. MATERIAL AND METHODNinety patients of ASA I and II of age group 20yrs-60yrs of either sex were included in our study undergoing upper limb surgeries in Gandhi Medical College and Hamidia Hospital, Bhopal (MP). The patients were randomly divided into three groups:-Group I (n= 30) : Bupivacaine 0.5%-5mg/ml-30ml, Group II (n= 30) : Levobupivacaine 0.5%-5mg/ml --30ml, Group III (n=30) : Ropivacaine 0.5%-5mg/ml --30ml onset time of sensory and motor block, duration of sensory and motor block and duration of pain relief were recorded. RESULTAnalysis revealed that Ropivacaine provided fast onset of action and better quality of anaesthesia and analgesia than bupivacaine and levobupivacaine when used in axillary brachial plexus blockade. There was no significant difference in duration of sensory blockade between three groups. But Ropivacaine showed lesser duration of motor blockade when compared to bupivacaine and levobupivacaine. CONCLUSIONWe conclude that 0.5% 30ml of ropivacaine in axillary brachial plexus block is a safe dose, allowing practitioner to produce a fast onset of sensory block and long duration of peripheral nerve block with excellent postoperative analgesia and stable hemodynamics. So ropivacaine is a better option for forearm surgeries in axillary brachial plexus block when compared with bupivacaine and levobupivacaine.

show abstract

Axillary brachial plexus block with ropivacaine 7.5 mg/ml

Abstract: Ropivacaine 7.5 mg/ml, 40 ml, produces axillary plexus block of similar onset and duration but better quality than 40 ml of bupivacaine 5.0 mg/ml.

Cited by 78 publications

References 8 publications

Relative Nerve Blocking Properties of Bupivacaine and Ropivacaine in Dogs Undergoing Brachial Plexus Block Using a Nerve Stimulator

Relative Nerve Blocking Properties of Bupivacaine and Ropivacaine in Dogs Undergoing Brachial Plexus Block Using a Nerve Stimulator

Pharmacokinetics and efficacy of 40 ml ropivacaine 7.5 mg/ml (300 mg), for axillary brachial plexus block — an open pilot study

Compar Ison Study of Bupivacaine, Levobupivacaine and Ropivacaine in Axillary Brachial Plexus Block: A Clinical Study

Contact Info

Product

Resources

About